

Applicants : King et al.	Atty. Dkt. No.	:	891-A-PCT-US
USSN : 10/593,217	Art Unit	:	1623
Filed : 9-15-2006	Date of office action	:	5-14-2008
Examiner : Krishnan Ganapathy	Date of response	:	08-14-2008
Page : 3			

Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-33. (Canceled)

34. (New) A composition comprising an amount of VNP40101M and an amount of cytarabine, wherein the VNP40101M and cytarabine produce synergistic effects when used in combination in treating tumor.

35. (New) A composition comprising an amount of VNP40101M and an amount of fludarabine, wherein the VNP40101M and fludarabine produce synergistic effects when used in combination in treating tumor.

36. (New) A method of treating tumor in a subject, comprising the step of administering to the subject an effective amount of VNP40101M and an effective amount of cytarabine, wherein the amounts of VNP40101M and cytarabine administered provide a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or cytarabine individually.

37. (New) The method of claim 36, wherein the tumor is a solid malignant tumor, leukemia or lymphoma.

38. (New) The method of claim 36, wherein VNP40101M and cytarabine are administered concurrently or sequentially.

Applicants : King et al.	Atty. Dkt. No.	:	891-A-PCT-US
USSN : 10/593,217	Art Unit	:	1623
Filed : 9-15-2006	Date of office action	:	5-14-2008
Examiner : Krishnan Ganapathy	Date of response	:	08-14-2008
Page : 4			

39. (New) The method of claim 36, wherein VNP40101M and cytarabine are administered intravenously, subcutaneously, or orally.
40. (New) The method of claim 37, wherein the leukemia is acute myelogenous leukemia.
41. (New) The method of claim 36, wherein VNP40101M is administered between 100 and 1000 mg/m² and cytarabine is administered between 500 and 5000 mg/m².
42. (New) The method of claim 36, wherein the subject is a human.
43. (New) A method of treating tumor in a subject, comprising the step of administering to the subject an effective amount of VNP40101M and an effective amount of fludarabine, wherein the amounts of VNP40101M and fludarabine administered provide a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or fludarabine individually.
44. (New) The method of claim 43, wherein the tumor is solid malignant tumor, leukemia or lymphoma.
45. (New) The method of claim 43, wherein VNP40101M and fludarabine are administered concurrently or sequentially.
46. (New) The method of claim 43, wherein VNP40101M and fludarabine are administered intravenously, subcutaneously, or orally.

Applicants :	King et al.	Atty. Dkt. No.	:	891-A-PCT-US	
USSN	:	10/593,217	Art Unit	:	1623
Filed	:	9-15-2006	Date of office action	:	5-14-2008
Examiner	:	Krishnan Ganapathy	Date of response	:	08-14-2008
Page	:	5			

47. (New) The method of claim 44, wherein the leukemia is acute myelogenous leukemia.

48. (New) The method of claim 43, wherein the subject is a human.